Skip to main content
SpringerLink
Log in

Absetzen oder belassen?

Pro- und Kontra ACE-Hemmer bei geplanter Insektengift-SIT

  • Allergologie aktuell
  • Published:
Allergo Journal Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Aberer W et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047–54

    Article  PubMed  Google Scholar 

  2. Ruëff F, Przybilla B, Biló MB, Müller U, Scheipl F, Seitz MJ et al. Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PlosONE 2013;8:e63233

    Article  Google Scholar 

  3. Ruëff F, Vos B, Oude Elberink J, Bender A, Chatelain R, Dugas-Breit S et al. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy. Clin Exp Allergy 2014:44:736–46

    Article  PubMed  Google Scholar 

  4. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clinical & Experimental Allergy 2014;44:747–55

    Article  CAS  Google Scholar 

  5. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol. 2004;114:371–6

    Article  PubMed  Google Scholar 

  6. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. et al. J Allergy Clin Immunol 2005;115:606–10

    Article  PubMed  Google Scholar 

Literatur

  1. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a metaanalysis of major clinical trials. J Am Coll Cardiol 2003;41:1529–38

    Article  PubMed  CAS  Google Scholar 

  2. Stoevesandt J, Hain J, Stolze I, Kerstan A, Trautmann A. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clinical & Experimental Allergy 2014;44:747–55

    Article  CAS  Google Scholar 

  3. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008;101:426–30

    Article  PubMed  Google Scholar 

  4. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130: 698–704

    Article  PubMed  Google Scholar 

Download references

Author information

Consortia

Urban & Vogel GmbH

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Urban & Vogel GmbH. Absetzen oder belassen?. Allergo J 23, 96–98 (2014). https://doi.org/10.1007/s15007-014-0654-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15007-014-0654-1

Search

Navigation